All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
COVID-19 has been reported to damage multiple organ systems, primarily the respiratory system, which contributes to the high mortality rate among patients. In addition, it causes venous thromboembolism (VTE), arterial thrombosis, and blockage in the microcirculation. The incidence of thromboembolic events may vary among patients; some comorbidities, such as hypertension, obesity, diabetes or cardiovascular disease, chronic respiratory disease, and cancer, may increase the risk of these events in patients with SARS-CoV-2 infection. The estimations of the incidence widely depend on screening for the presence of these events and being treated in an intensive care unit (ICU).
Patients with myeloproliferative neoplasms (MPN) are known to be at a higher risk of experiencing thrombotic complications, along with spontaneous or drug-related bleeding, compared with the general population. This disposition may put patients in a more vulnerable position for thrombotic events.
MPN Hub Steering Committee member Tiziano Barbui and colleagues have conducted the international MPN-COVID study (NCT04385160) to collect related data on COVID-19 and the incidence of thrombosis/bleeding events in patients with MPN, i.e. essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), and to identify associated predictors. The results have recently been published in Blood Cancer Journal,1 and here, we are pleased to summarize key points.
The analysis included 162 patients; the incidence and types of thrombosis and bleeding were reported with a median follow-up duration of 50.5 days (interquartile range [IQR], 16.0–69.0) and are presented in Table 1. A total of 22 thrombohemorrhagic events were observed in 19 patients.
Table 1. Thrombosis and bleeding events by MPN type1
|
Total |
ET |
PV |
MF |
Pre-MF |
p value† |
---|---|---|---|---|---|---|
Thrombosis |
||||||
Patients with thrombosis, n (%) |
14 (8.6) |
8 (16.7) |
2 (4.8) |
3 (5.4) |
1 (6.3) |
0.13 |
Thrombotic events, n (%) |
15 (10.0) |
9 (18.8) |
2 (4.8) |
3 (5.4) |
1 (6.3) |
0.35 |
Arterial, n (%) |
3 (1.9) |
1 (2.1) |
0 (0.0) |
1 (1.8) |
1 (6.3) |
0.47 |
Venous, n (%) |
12 (7.4) |
8 (16.7) |
2 (4.8) |
2 (3.6) |
0 (0.0) |
0.031 |
Median time to any thrombosis, days (IQR) |
11.5 (4.0–25.0) |
7.0 (2.5–11.5) |
8.0 (1.0–15.0) |
25.0 (16.0–32.0) |
28.0 (28.0–28.0) |
0.27 |
Median time to PE, days (IQR) |
8.0 (0.0–14.0) |
4.0 (0.0–8.0) |
7.0 (0.0–14.0) |
27.5 (24.0–31.0) |
― |
0.097 |
Bleeding |
||||||
Patients with bleeding, n (%) |
7 (4.3) |
1 (2.1) |
2 (4.9) |
4 (7.1) |
0 (0.0) |
0.51 |
Transfusion needed, n (%) |
5 (3.1) |
1 (2.1) |
0 (0.0) |
4 (7.1) |
― |
0.030 |
Median time to bleeding, days (IQR) |
16.0 (13.0–24.0) |
14.0 (14.0–14.0) |
23.0 (16.0–30.0) |
17.5 (6.5–23.0) |
― |
0.50 |
AMI, acute myocardial infarction; DVT, deep vein thrombosis of the legs; ET, essential thrombocythemia; IQR, interquartile range; MF, myelofibrosis; MPN, myeloproliferative neoplasms; PAT, peripheral arterial thrombosis; PE, pulmonary embolism; pre-PMF; prefibrotic MF; PV, polycythemia vera; SVT, superficial vein thrombosis. |
The analysis of cumulative incidence demonstrated the following:
Multivariate analysis confirmed the following three markers as independently associated with thrombosis risk:
The overall rate of thromboembolic events in patients with MPN and COVID-19 was 8.6% (n = 14). Strikingly, most of these events were VTE, indicating an association of VTE events observed in this study with COVID-19 rather than MPN, where arterial thrombosis is more common. However, patients with ET and COVID-19 experienced significantly more VTEs compared with patients with PV and MF, where the event rate was similar to patients with COVID-19 but without MPN, who were treated on regular wards. Vascular events occurred shortly after hospitalization and were associated with shorter survival. Independent risk factors for thrombosis were an ET phenotype, elevated NLR, and transfer to ICU. While most thrombotic events occurred within 15 days of COVID-19 onset, bleeding events were more frequent ~2 weeks after COVID-19 onset.
The authors acknowledged that the evaluation of risk factors for thrombohemorrhagic events may be confounded with the low number of patients and the retrospective design.
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox